NovoCure (NVCR) Net Income towards Common Stockholders (QoQ) (2014 - 2026)
NovoCure (NVCR) Net Income towards Common Stockholders (QoQ) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.81 Bn | 193.21 Bn | 7.27 Bn |
| 2 | Stryker | 127.76 Bn | 124.28 Bn | 4.50 Bn |
| 3 | Medtronic | 118.77 Bn | 109.55 Bn | 6.41 Bn |
| 4 | Boston Scientific | 73.25 Bn | 72.71 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn |
| 6 | Dexcom | 34.43 Bn | 32.49 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.88 Bn | 31.77 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn |
| 9 | Steris | 23.11 Bn | 22.63 Bn | 684.20 Mn |
| 10 | NovoCure | 2.03 Bn | 1.59 Bn | 142.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77.99% |
| Mar 31, 2026 | -190.37% |
| Dec 31, 2025 | 34.27% |
| Sep 30, 2025 | 7.15% |
| Jun 30, 2025 | -16.96% |
| Mar 31, 2025 | 47.94% |
| Dec 31, 2024 | -115.64% |
| Sep 30, 2024 | 8.40% |
| Jun 30, 2024 | 13.89% |
| Mar 31, 2024 | 17.67% |
| Dec 31, 2023 | 4.86% |
| Sep 30, 2023 | 13.82% |
| Jun 30, 2023 | -8.21% |
| Mar 31, 2023 | -42.24% |
| Dec 31, 2022 | -40.36% |
| Sep 30, 2022 | -10.70% |
| Jun 30, 2022 | -416.63% |
| Mar 31, 2022 | 82.44% |
| Dec 31, 2021 | -101.60% |
| Sep 30, 2021 | 10.36% |